Confirmations for antiviral remdesivir, less mortality and long-Covid - Medicine. (HANDLE) Three studies presented during the Conference on Retroviruses and Opportunistic Infections (Croi) held in Denver (USA) showed how it can reduce some symptoms and mortality in immunocompromised people hospitalized for Covid.
“The real-world data presented at the Croi conference continues to reinforce remdesvir's robust efficacy and safety profile as well as the drug's potential benefits in people with Covid-19,” said Frank Duff, senior vice president, Virology Therapeutic Area head of Gilead Sciences.